Audrey R. Odom John
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Audrey R. Odom John has a total of 599 co-authors. Here are the top co-authors by number of shared publications:
- Justin J. Miller
Department of Biochemistry and Biophysics, University of Pennsylvania
14 shared publications - Rachel L. Edwards
Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA
13 shared publications - Amalia Z. Berna
Department of Pediatrics, Children’s Hospital of Philadelphia
8 shared publications - Ann M. Guggisberg
Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA
8 shared publications Andrew J. Jezewski
Affiliations Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, United States of America, Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America
6 shared publicationsElikplim H. Akaho
Division of Infectious Diseases, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA
6 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Cryptosporidiosis at a Crossroads
- 28 October 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Open AccessCryptosporidiosis at a Crossroads
- Open Access
- 30 June 2026
- Published by American Society for Microbiology in mSphere
- Vol. 11 (6) , e0022226
Viral infections alter the human salivary volatilome
The volatile metabolome, or volatilome, contains a wealth of information regarding individual health. Two parallel approaches can detect patterns of these volatile metabolites: chemometric analyses employing gas chromatography-mass spectrometry (GC-MS) or “noses” (trained animals or so-called electronic noses). While “noses” are exquisite odor discrimination tools, chemometric analyses are superior for determining the chemical identity of odorants related to disease conditions. Without identifying compounds altered by disease, it is difficult to uncover the responsible mechanism(s) and develop effective diagnostic tools. To understand how viral pathogens may alter the human volatilome, we collected saliva from healthy patients and patients with confirmed viral infections. Using headspace GC-MS analyses, we examined associations between 85 salivary volatiles and specific viral pathogens. Twenty-eight salivary volatiles were up- or downregulated (in relation to the healthy condition) by infection with one or more viral pathogens. Further examination indicated that salivary volatiles encode some level of viral specificity. In particular, SARS-CoV-2 infection produced a unique volatile pattern differing from several other common viral respiratory infections. IMPORTANCE: This research examined alterations of the salivary volatilome caused by confirmed respiratory virus infections. Results indicate that the salivary volatilome may specify the offending pathogen for improved clinical outcomes.
- 30 June 2026
- Published by American Society for Microbiology in mSphere
- Vol. 11 (6) , e0022226
Open AccessViral infections alter the human salivary volatilome
The volatile metabolome, or volatilome, contains a wealth of information regarding individual health. Two parallel approaches can detect patterns of these volatile metabolites: chemometric analyses employing gas chromatography-mass spectrometry (GC-MS) or “noses” (trained animals or so-called electronic noses). While “noses” are exquisite odor discrimination tools, chemometric analyses are superior for determining the chemical identity of odorants related to disease conditions. Without identifying compounds altered by disease, it is difficult to uncover the responsible mechanism(s) and develop effective diagnostic tools. To understand how viral pathogens may alter the human volatilome, we collected saliva from healthy patients and patients with confirmed viral infections. Using headspace GC-MS analyses, we examined associations between 85 salivary volatiles and specific viral pathogens. Twenty-eight salivary volatiles were up- or downregulated (in relation to the healthy condition) by infection with one or more viral pathogens. Further examination indicated that salivary volatiles encode some level of viral specificity. In particular, SARS-CoV-2 infection produced a unique volatile pattern differing from several other common viral respiratory infections. IMPORTANCE: This research examined alterations of the salivary volatilome caused by confirmed respiratory virus infections. Results indicate that the salivary volatilome may specify the offending pathogen for improved clinical outcomes.
- Open Access
Breath volatile profiling reveals a diagnostic signature of MASLD in children
Background & Aims: Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) is the leading cause of chronic liver disease in children. However, accurate, noninvasive diagnostic tools remain limited. Current screening methods are invasive or lack sensitivity. Breath-based volatile organic compound (VOC) analysis offers a simple approach with potential for point-of-care screening. This study aimed to identify and validate breath VOC signatures of pediatric MASLD. Approach & Results: We conducted a prospective IRB-approved cohort study at the Children’s Hospital of Philadelphia (CHOP). Children aged 7–20 years with MASLD (n=22), as defined by hepatic steatosis either by liver biopsy or imaging and 1 cardiometabolic risk factor, and a control group without MASLD (n=20) were enrolled. Breath samples were collected using a standardized protocol and analyzed by untargeted comprehensive two-dimensional gas chromatography-mass spectrometry (GC×GC-MS). Machine learning and unsupervised clustering were applied to identify discriminatory VOCs and assess heterogeneity. Untargeted GC×GC-MS analysis identified a distinct breath VOC signature in children with MASLD compared with non-MASLD controls. A Random Forest model achieved a sensitivity of 73% and specificity of 65%, with AUC of 0.84. The VOC 2,4-dimethyl-1-heptene demonstrated strong diagnostic performance in the discovery cohort with a sensitivity of 85%, specificity of 77% and an AUC of 0.81. Unsupervised clustering revealed four MASLD subgroups with distinct volatile phenotypes associated with differences in liver enzymes and metabolic parameters. External validation in a second pediatric cohort confirmed reproducible reductions in o/p-xylene in subjects with MASLD. Conclusions: Pediatric MASLD is associated with a reproducible breath VOC signature identified by untargeted GC×GC-MS. These findings support breath analysis as a scalable, noninvasive screening and stratification tool for pediatric MASLD and warrant validation in larger, longitudinal studies. IMPACT AND IMPLICATIONS: Pediatric MASLD lacks scalable, noninvasive diagnostic tools capable of early identification of at-risk children, providing strong scientific justification for the development of breath-based biomarkers. This study demonstrates that untargeted breath VOC profiling can distinguish children with MASLD from controls and reveals biologically meaningful heterogeneity in breath signatures, highlighting the potential of breath analysis for both detection and risk stratification. These findings are most relevant to physicians managing children with cardiometabolic risk and to researchers developing noninvasive liver biomarkers. Broader validation is required before clinical implementation.
Open AccessBreath volatile profiling reveals a diagnostic signature of MASLD in children
Background & Aims: Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) is the leading cause of chronic liver disease in children. However, accurate, noninvasive diagnostic tools remain limited. Current screening methods are invasive or lack sensitivity. Breath-based volatile organic compound (VOC) analysis offers a simple approach with potential for point-of-care screening. This study aimed to identify and validate breath VOC signatures of pediatric MASLD. Approach & Results: We conducted a prospective IRB-approved cohort study at the Children’s Hospital of Philadelphia (CHOP). Children aged 7–20 years with MASLD (n=22), as defined by hepatic steatosis either by liver biopsy or imaging and 1 cardiometabolic risk factor, and a control group without MASLD (n=20) were enrolled. Breath samples were collected using a standardized protocol and analyzed by untargeted comprehensive two-dimensional gas chromatography-mass spectrometry (GC×GC-MS). Machine learning and unsupervised clustering were applied to identify discriminatory VOCs and assess heterogeneity. Untargeted GC×GC-MS analysis identified a distinct breath VOC signature in children with MASLD compared with non-MASLD controls. A Random Forest model achieved a sensitivity of 73% and specificity of 65%, with AUC of 0.84. The VOC 2,4-dimethyl-1-heptene demonstrated strong diagnostic performance in the discovery cohort with a sensitivity of 85%, specificity of 77% and an AUC of 0.81. Unsupervised clustering revealed four MASLD subgroups with distinct volatile phenotypes associated with differences in liver enzymes and metabolic parameters. External validation in a second pediatric cohort confirmed reproducible reductions in o/p-xylene in subjects with MASLD. Conclusions: Pediatric MASLD is associated with a reproducible breath VOC signature identified by untargeted GC×GC-MS. These findings support breath analysis as a scalable, noninvasive screening and stratification tool for pediatric MASLD and warrant validation in larger, longitudinal studies. IMPACT AND IMPLICATIONS: Pediatric MASLD lacks scalable, noninvasive diagnostic tools capable of early identification of at-risk children, providing strong scientific justification for the development of breath-based biomarkers. This study demonstrates that untargeted breath VOC profiling can distinguish children with MASLD from controls and reveals biologically meaningful heterogeneity in breath signatures, highlighting the potential of breath analysis for both detection and risk stratification. These findings are most relevant to physicians managing children with cardiometabolic risk and to researchers developing noninvasive liver biomarkers. Broader validation is required before clinical implementation.
- 8 May 2026
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 157 (6)
Malaria in Children at 9 US Hospitals: 2016–2023
OBJECTIVES: This study set out to describe imported pediatric malaria in the United States over an 8-year period, including patient demographics, clinical outcomes, and risk factors for severe disease. METHODS: A retrospective descriptive study of pediatric patients treated for malaria at 9 hospitals in the United States from 2016 to 2023 was conducted to analyze patient demographics, clinical outcomes, and risk factors for severe malaria. RESULTS: A total of 171 children were treated across the 9 US hospitals included in this study from 2016 to 2023. Most patients had traveled to West Africa to visit friends and relatives. Fever was the most common symptom recorded (90%), and most reported at least 1 abdominal symptom (66%). Thirty-two percent of patients were diagnosed with severe malaria. No deaths occurred. Delayed diagnoses were common (26%), occurred at similar rates across all hospitals in the study, and were a risk factor for severe malaria. CONCLUSIONS: Delayed diagnoses of travel-acquired malaria were common for pediatric patients presenting to hospitals in the United States and are associated with higher risk for severe malaria, which is associated with longer hospitalizations and increased morbidity. Chemoprophylaxis against travel-acquired malaria and prompt diagnosis of imported cases are crucial to improving patient outcomes.
- 8 May 2026
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 157 (6)
Malaria in Children at 9 US Hospitals: 2016–2023
OBJECTIVES: This study set out to describe imported pediatric malaria in the United States over an 8-year period, including patient demographics, clinical outcomes, and risk factors for severe disease. METHODS: A retrospective descriptive study of pediatric patients treated for malaria at 9 hospitals in the United States from 2016 to 2023 was conducted to analyze patient demographics, clinical outcomes, and risk factors for severe malaria. RESULTS: A total of 171 children were treated across the 9 US hospitals included in this study from 2016 to 2023. Most patients had traveled to West Africa to visit friends and relatives. Fever was the most common symptom recorded (90%), and most reported at least 1 abdominal symptom (66%). Thirty-two percent of patients were diagnosed with severe malaria. No deaths occurred. Delayed diagnoses were common (26%), occurred at similar rates across all hospitals in the study, and were a risk factor for severe malaria. CONCLUSIONS: Delayed diagnoses of travel-acquired malaria were common for pediatric patients presenting to hospitals in the United States and are associated with higher risk for severe malaria, which is associated with longer hospitalizations and increased morbidity. Chemoprophylaxis against travel-acquired malaria and prompt diagnosis of imported cases are crucial to improving patient outcomes.
- Open Access
The cellular esterase FrmB controls metabolic homeostasis and small colony variant formation in Staphylococcus aureus
Staphylococcus aureus is a gram-positive bacterium that commonly colonizes the nasal passage, axilla, groin, and gastrointestinal tract of adults and adolescents. Although frequently nonpathogenic, S. aureus can infect most tissue types with clinical outcomes ranging from mild to fatal. The ability of S. aureus to persist and infect multiple body sites is driven largely by its metabolism. S. aureus can metabolize a wide range of niche-specific carbon sources, which contributes significantly to its persistence. Specifically, the utilization of glycolytic intermediates and pyruvate are associated with S. aureus bacterial burden and survival in the host. In this study, we establish the biological role of a serine hydrolase, FrmB, and evaluate its impact on S. aureus carbon metabolism. Using targeted metabolomics on S. aureus strains with and without FrmB, we find that FrmB is required for central carbon metabolic homeostasis. Mechanistically, we find that FrmB controls the enzymatic activity of the crucial rate-limiting enzyme, pyruvate dehydrogenase, which links glycolysis to the downstream tricarboxylic acid (TCA) cycle. Importantly, we find that the metabolic derangements in the absence of FrmB impact the ability of S. aureus to utilize pyruvate as a primary carbon source and reduce fitness. Finally, we demonstrate that FrmB is important for the formation of small colony variants (SCVs), a clinically relevant metabolic transition that is associated with chronic infection and antibiotic resistance.
Open AccessThe cellular esterase FrmB controls metabolic homeostasis and small colony variant formation in Staphylococcus aureus
Staphylococcus aureus is a gram-positive bacterium that commonly colonizes the nasal passage, axilla, groin, and gastrointestinal tract of adults and adolescents. Although frequently nonpathogenic, S. aureus can infect most tissue types with clinical outcomes ranging from mild to fatal. The ability of S. aureus to persist and infect multiple body sites is driven largely by its metabolism. S. aureus can metabolize a wide range of niche-specific carbon sources, which contributes significantly to its persistence. Specifically, the utilization of glycolytic intermediates and pyruvate are associated with S. aureus bacterial burden and survival in the host. In this study, we establish the biological role of a serine hydrolase, FrmB, and evaluate its impact on S. aureus carbon metabolism. Using targeted metabolomics on S. aureus strains with and without FrmB, we find that FrmB is required for central carbon metabolic homeostasis. Mechanistically, we find that FrmB controls the enzymatic activity of the crucial rate-limiting enzyme, pyruvate dehydrogenase, which links glycolysis to the downstream tricarboxylic acid (TCA) cycle. Importantly, we find that the metabolic derangements in the absence of FrmB impact the ability of S. aureus to utilize pyruvate as a primary carbon source and reduce fitness. Finally, we demonstrate that FrmB is important for the formation of small colony variants (SCVs), a clinically relevant metabolic transition that is associated with chronic infection and antibiotic resistance.
- 2 February 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (5) , e1085-e1087
Implementation Does Not Occur in a Vacuum: Sustaining a Comprehensive and Global Vision for HIV Research
Despite transformative advances in antiretroviral therapy, human immunodeficiency virus (HIV) remains a lifelong condition driven by durable viral reservoirs, chronic immune dysfunction, and complex interactions with host biology, coinfections, and aging. While implementation science is essential to ensure that effective interventions reach populations most affected by HIV, implementation cannot succeed in isolation from continued discovery or from the political and social contexts in which care is delivered. This editorial highlights critical gaps in our understanding of sex-based immunologic differences, tissue-specific viral persistence, resistance evolution, and the long-term inflammatory and metabolic consequences of treated HIV—gaps that directly constrain the durability, equity, and scalability of prevention, treatment, and cure strategies. We further emphasize that successful translation depends on stable policy environments, sustained public investment, and trust-based partnerships with affected communities, without which even highly effective biomedical advances fail to achieve impact. Sustained investment across the full translational spectrum—from basic and mechanistic science through clinical, behavioral, and implementation research—is therefore essential. HIV research has repeatedly served as a model system driving advances across immunology, vaccinology, oncology, aging, and pandemic preparedness, underscoring its broader relevance to human infectious diseases.
- 2 February 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (5) , e1085-e1087
Implementation Does Not Occur in a Vacuum: Sustaining a Comprehensive and Global Vision for HIV Research
Despite transformative advances in antiretroviral therapy, human immunodeficiency virus (HIV) remains a lifelong condition driven by durable viral reservoirs, chronic immune dysfunction, and complex interactions with host biology, coinfections, and aging. While implementation science is essential to ensure that effective interventions reach populations most affected by HIV, implementation cannot succeed in isolation from continued discovery or from the political and social contexts in which care is delivered. This editorial highlights critical gaps in our understanding of sex-based immunologic differences, tissue-specific viral persistence, resistance evolution, and the long-term inflammatory and metabolic consequences of treated HIV—gaps that directly constrain the durability, equity, and scalability of prevention, treatment, and cure strategies. We further emphasize that successful translation depends on stable policy environments, sustained public investment, and trust-based partnerships with affected communities, without which even highly effective biomedical advances fail to achieve impact. Sustained investment across the full translational spectrum—from basic and mechanistic science through clinical, behavioral, and implementation research—is therefore essential. HIV research has repeatedly served as a model system driving advances across immunology, vaccinology, oncology, aging, and pandemic preparedness, underscoring its broader relevance to human infectious diseases.
- Open Access
- 22 January 2026
- Published by Elsevier in Cell Metabolism
- Vol. 38 (4) , 779-793.e8
The gut microbiota shapes the human and murine breath volatilome
- 22 January 2026
- Published by Elsevier in Cell Metabolism
- Vol. 38 (4) , 779-793.e8
Open AccessThe gut microbiota shapes the human and murine breath volatilome
- Open Access
- 3 December 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (49)
Machine learning enables de novo multiepitope design of Plasmodium falciparum circumsporozoite protein to target trimeric L9 antibody
Currently approved vaccines for the prevention of malaria provide only partial protection against disease due to high variability in the quality of induced antibodies. These vaccines present the unstructured central repeat region, as well as the C-terminal domain, of the circumsporozoite protein ( Pf CSP) of the malaria parasite, Plasmodium falciparum [K. L. Williams et al ., Nat. Med. 30 ,1–13 (2024)]. A recently discovered protective monoclonal antibody, L9, recognizes three structured copies of the Pf CSP minor repeat. Similarly to other highly potent antimalarial antibodies, L9 relies on critical homotypic interactions between antibodies for its high protective efficacy [P. Tripathi et al. , Structure 31 , 480–491.e4 (2023); G. M. Martin et al. , Nat. Commun. 14 ,2815 (2023)]. Here, we report the design of antigens scaffolding one copy of Pf CSP’s minor repeat capable of binding L9. To design antigens capable of presenting multiple, structure-based epitopes in one scaffold, we developed a machine learning– driven structural antigen design pipeline, MESODID, tailored to focus on multiepitope vaccine targets. We use this pipeline to design multiple scaffolds that present three copies of the Pf CSP minor repeat. A 3.6 Å cryo-EM structure of our top design, minor repeat targeting immunogen (M-TIM), demonstrates that M-TIM successfully orients three copies of L9, effectively recapitulating its critical homotypic interactions. The wide prevalence of repeated epitopes in key vaccine targets, such as HIV-1 Envelope, SARS-CoV-2 spike, and Influenza Hemagglutinin, suggests that MESODID will have broad utility in creating antigens that incorporate such epitopes, offering a powerful approach to developing vaccines against a range of challenging infections, including malaria.
- 3 December 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (49)
Open AccessMachine learning enables de novo multiepitope design of Plasmodium falciparum circumsporozoite protein to target trimeric L9 antibody
Currently approved vaccines for the prevention of malaria provide only partial protection against disease due to high variability in the quality of induced antibodies. These vaccines present the unstructured central repeat region, as well as the C-terminal domain, of the circumsporozoite protein ( Pf CSP) of the malaria parasite, Plasmodium falciparum [K. L. Williams et al ., Nat. Med. 30 ,1–13 (2024)]. A recently discovered protective monoclonal antibody, L9, recognizes three structured copies of the Pf CSP minor repeat. Similarly to other highly potent antimalarial antibodies, L9 relies on critical homotypic interactions between antibodies for its high protective efficacy [P. Tripathi et al. , Structure 31 , 480–491.e4 (2023); G. M. Martin et al. , Nat. Commun. 14 ,2815 (2023)]. Here, we report the design of antigens scaffolding one copy of Pf CSP’s minor repeat capable of binding L9. To design antigens capable of presenting multiple, structure-based epitopes in one scaffold, we developed a machine learning– driven structural antigen design pipeline, MESODID, tailored to focus on multiepitope vaccine targets. We use this pipeline to design multiple scaffolds that present three copies of the Pf CSP minor repeat. A 3.6 Å cryo-EM structure of our top design, minor repeat targeting immunogen (M-TIM), demonstrates that M-TIM successfully orients three copies of L9, effectively recapitulating its critical homotypic interactions. The wide prevalence of repeated epitopes in key vaccine targets, such as HIV-1 Envelope, SARS-CoV-2 spike, and Influenza Hemagglutinin, suggests that MESODID will have broad utility in creating antigens that incorporate such epitopes, offering a powerful approach to developing vaccines against a range of challenging infections, including malaria.
- Open Access
- 4 November 2025
- Published by American Society for Microbiology in ASM Case Reports
- Vol. 1 (6)
Pocapavir for neonatal enteroviral sepsis: limitations of rapid viral sequencing on treatment decisions
Background: Neonatal enterovirus infection can be severe and life-threatening, and there is ongoing interest in the development of antiviral compounds; however, their clinical efficacy has not been definitively proven. Case Summary: We describe a case of neonatal enterovirus infection treated with the investigational therapeutic pocapavir, a viral capsid inhibitor. We describe the medical decision-making regarding the choice to offer pocapavir therapy. Because of clinical uncertainty about whether pocapavir contributed to clinical improvement, we performed sequencing of the viral genome and modeled the pocapavir pocket-binding site for evidence of genetic and protein changes before or after the initiation of pocapavir that might confer antiviral resistance. Conclusion: This case and our findings reveal the challenges in interpreting sequence analysis of clinical enterovirus isolates to inform clinical decision-making regarding the use of pocapavir for the treatment of neonatal enterovirus.
- 4 November 2025
- Published by American Society for Microbiology in ASM Case Reports
- Vol. 1 (6)
Open AccessPocapavir for neonatal enteroviral sepsis: limitations of rapid viral sequencing on treatment decisions
Background: Neonatal enterovirus infection can be severe and life-threatening, and there is ongoing interest in the development of antiviral compounds; however, their clinical efficacy has not been definitively proven. Case Summary: We describe a case of neonatal enterovirus infection treated with the investigational therapeutic pocapavir, a viral capsid inhibitor. We describe the medical decision-making regarding the choice to offer pocapavir therapy. Because of clinical uncertainty about whether pocapavir contributed to clinical improvement, we performed sequencing of the viral genome and modeled the pocapavir pocket-binding site for evidence of genetic and protein changes before or after the initiation of pocapavir that might confer antiviral resistance. Conclusion: This case and our findings reveal the challenges in interpreting sequence analysis of clinical enterovirus isolates to inform clinical decision-making regarding the use of pocapavir for the treatment of neonatal enterovirus.
- Open Access
- 30 September 2025
- Published by American Society for Microbiology in mSphere
- Vol. 10 (9) , e0035125
Sensitive, non-invasive detection of chronic wasting disease in wild and captive white-tailed deer using fecal volatile profiling
Chronic wasting disease (CWD) is a universally fatal, transmissible prion disease affecting cervids. Primarily found among deer populations in North America, the disease has spread across the continent and made forays into Europe and Asia as well. Currently, accurate methods for detecting CWD infection require postmortem dissection of the lymph nodes and brainstem of affected animals. New, high-sensitivity methods of identifying CWD in living animals are sorely needed to help curb the spread of this devastating disease in captive and wild deer. Here, we use two-dimensional gas chromatography-mass spectrometry (GCxGC-MS) to detect volatile organic compounds (VOCs) released from feces of white-tailed deer (WTD) for differentiation of the feces of CWD-negative and CWD-positive animals. We report 4 discrete VOCs in captive WTD and 10 discrete VOCs in wild WTD, with which we can discriminate CWD-positive and CWD-negative samples. Additionally, we evaluate the ability to detect biomarkers associated with CWD early during disease progression, by comparing samples from the early stage of infection with samples from the late stage and uninfected WTD. Our data suggest that detection of VOCs from the feces of WTD—both in captive and wild populations—can serve as a highly sensitive and non-invasive technique for identifying CWD infection in living animals. IMPORTANCE: Chronic wasting disease (CWD) is a deadly, transmissible prion disease of cervids. The spread of CWD is increasing among both wild and captive deer populations; however, the options to detect in living animals are limited. Diagnosing CWD early would allow more effective control over the spread between animals and contamination of the environment. Our research presents a method of determining CWD infection through the detection of disease-associated odor molecules in the feces of affected deer. This methodology lays the foundation for rapid, non-invasive diagnosis of CWD in living white-tailed deer, allowing for the development of tools to enhance control of this devastating disease’s spread among both captive and wild populations.
- 30 September 2025
- Published by American Society for Microbiology in mSphere
- Vol. 10 (9) , e0035125
Open AccessSensitive, non-invasive detection of chronic wasting disease in wild and captive white-tailed deer using fecal volatile profiling
Chronic wasting disease (CWD) is a universally fatal, transmissible prion disease affecting cervids. Primarily found among deer populations in North America, the disease has spread across the continent and made forays into Europe and Asia as well. Currently, accurate methods for detecting CWD infection require postmortem dissection of the lymph nodes and brainstem of affected animals. New, high-sensitivity methods of identifying CWD in living animals are sorely needed to help curb the spread of this devastating disease in captive and wild deer. Here, we use two-dimensional gas chromatography-mass spectrometry (GCxGC-MS) to detect volatile organic compounds (VOCs) released from feces of white-tailed deer (WTD) for differentiation of the feces of CWD-negative and CWD-positive animals. We report 4 discrete VOCs in captive WTD and 10 discrete VOCs in wild WTD, with which we can discriminate CWD-positive and CWD-negative samples. Additionally, we evaluate the ability to detect biomarkers associated with CWD early during disease progression, by comparing samples from the early stage of infection with samples from the late stage and uninfected WTD. Our data suggest that detection of VOCs from the feces of WTD—both in captive and wild populations—can serve as a highly sensitive and non-invasive technique for identifying CWD infection in living animals. IMPORTANCE: Chronic wasting disease (CWD) is a deadly, transmissible prion disease of cervids. The spread of CWD is increasing among both wild and captive deer populations; however, the options to detect in living animals are limited. Diagnosing CWD early would allow more effective control over the spread between animals and contamination of the environment. Our research presents a method of determining CWD infection through the detection of disease-associated odor molecules in the feces of affected deer. This methodology lays the foundation for rapid, non-invasive diagnosis of CWD in living white-tailed deer, allowing for the development of tools to enhance control of this devastating disease’s spread among both captive and wild populations.